Latest results from ShigaPlexIM to be presented at the VASE conference 2022
Updated: Nov 30, 2022
29 November 2022
The Vaccines Against Shigella and ETEC (VASE) Conference is an international gathering dedicated to developing Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines. Hosted by PATH, a global non-profit organisation dedicated to achieving health equity, it’s an event for people like you who care about improving public health and saving lives by reducing diarrheal disease.
The latest results from EVI-coordinated ShigaPlexIM project funded by European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme. will be presented at the VASE conference 2022 to be held in Washington on 29 November–01 December 2022. Dr Aicha Sayeh, is representing EVI.
Four posters will present the epidemiological baseline studies that were conducted in the context of the ShigaPlexIM project at Groupe de Recherche Action en Santé (GRAS, Burkina Faso) and Centre for Infectious Disease Research in Zambia (CIDRZ, Zambia). These studies aimed at assessing the prevalence of Shigella and other enteric bacterial infections in children under five presenting with Severe-to-Moderate Diarrhoea (SMD). The results of this study will support the design of future efficacy trials for Shigella vaccine candidates.